ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 49 filers reported holding ALPINE IMMUNE SCIENCES INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,759,865 | -91.6% | 153,700 | -92.4% | 1.62% | -86.2% |
| Q2 2023 | $20,864,082 | +33.2% | 2,029,580 | 0.0% | 11.69% | +14.4% |
| Q1 2023 | $15,668,358 | +5.0% | 2,029,580 | 0.0% | 10.22% | +103.2% |
| Q4 2022 | $14,917,413 | +2.1% | 2,029,580 | 0.0% | 5.03% | -6.0% |
| Q3 2022 | $14,613,000 | -15.4% | 2,029,580 | 0.0% | 5.35% | -2.9% |
| Q2 2022 | $17,272,000 | -5.1% | 2,029,580 | 0.0% | 5.51% | +48.0% |
| Q1 2022 | $18,205,000 | -35.2% | 2,029,580 | 0.0% | 3.73% | -6.2% |
| Q4 2021 | $28,110,000 | +29.8% | 2,029,580 | 0.0% | 3.97% | +63.6% |
| Q3 2021 | $21,656,000 | +87.3% | 2,029,580 | +58.0% | 2.43% | +85.6% |
| Q2 2021 | $11,564,000 | -15.1% | 1,284,900 | 0.0% | 1.31% | +1.6% |
| Q1 2021 | $13,620,000 | -15.9% | 1,284,900 | 0.0% | 1.29% | -47.0% |
| Q4 2020 | $16,190,000 | +43.4% | 1,284,900 | 0.0% | 2.43% | -20.5% |
| Q3 2020 | $11,294,000 | – | 1,284,900 | – | 3.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |